NEURONAX is a biotechnological company developing first-in-class candidate-drugs supporting neural repair in order to treat traumatic or severe degenerative disorders of the central nervous system (CNS) and to contribute to restore neurological function, and thus to improve the quality of life of patients.

NEURONAX is focusing its development effort firstly on spinal cord injuries (SCI). Whereas no efficient treatment is currently available, the multi-functional activities of our lead candidate, NX210, suggest an important potential of this innovative compound in the treatment of traumatic injuries of the spinal cord, a huge unmet medical need. A program of preclinical regulatory studies has been successfully completed and a protocol of clinical trial is currently in preparation.